

Madrid, 15 october, 2023.


## CERTIFICATE

I, Dr. Luis Cabezón Gutierrez, Head of the Medical Oncology Department of Hospital Universitario de Torrejón in Torrejón de Ardoz, Madrid, Spain and Associate Professor of Medicine at Hospital Universitario Francisco de Vitoria in Madrid, certify that the statistical analysis of the article entitled "Systemic Inflammation Response Index (SIRI) and Weight Loss as Prognostic Factors in Metastatic Pancreatic Cancer: A Proof of Concept Study from the PANTHEIA-SEOM trial" has been carried out in accordance with the standards of quality, rigor, and good analytical practice.

The statistical analysis was carried out by Dr. Vilma Pacheco Barcia, Medical Oncology consultant at Hospital Universitario de Torrejón, based on her training applied to the statistical analysis of medical databases. The statistical analysis of this study has been revised and approved by all authors.

Previous publications that were produced by Dr. Vilma Pacheco Barcia, including statistical analysis, are listed below:

1. Pacheco-Barcia V, Mondéjar Solís R, France T, et al. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. *Pancreas*. 2019;48(5):e45-e47. doi:10.1097/MPA.0000000000001294
2. Gómez-León N, Pacheco-Barcia V, Ballesteros AI, Fraga J, Colomer R, Frieria A. Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. *Melanoma Res*. 2018;28(6):562-570. doi:10.1097/CMR.0000000000000466
3. Pacheco-Barcia V, Mondéjar R, Martínez-Sáez O, et al. Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. *Clin Colorectal Cancer*. 2019;18(3):e287-e293. doi:10.1016/j.clcc.2019.05.009
4. Pacheco-Barcia V, Mondéjar Solís R, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. *Pancreatol*. 2020;20(2):254-264. doi:10.1016/j.pan.2019.12.010
5. Pacheco-Barcia V, Muñoz A, Castro E, et al. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. *Cancers (Basel)*. 2022;14(12):2950. Published 2022 Jun 15. doi:10.3390/cancers14122950

  
Dr. Luis Cabezón Gutiérrez

Head of Department  
Medical Oncology  
Hospital Universitario de Torrejón, Torrejón de Ardoz  
Madrid, Spain  
Email address: 